Literature DB >> 21168336

Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid.

Francesca Curreli1, Hongtao Zhang, Xihui Zhang, Ilya Pyatkin, Zagorodnikov Victor, Andrea Altieri, Asim K Debnath.   

Abstract

The hydrophobic cavity of the C-terminal domain (CTD) of HIV-1 capsid has been recently validated as potential target for antiviral drugs by peptide-based inhibitors; however, there is no report yet of any small molecule compounds that target this hydrophobic cavity. In order to fill this gap and discover new classes of ant-HIV-1 inhibitors, we undertook a docking-based virtual screening and subsequent analog search, and medicinal chemistry approaches to identify small molecule inhibitors against this target. This article reports for the first time, to the best of our knowledge, identification of diverse classes of inhibitors that efficiently inhibited the formation of mature-like viral particles verified under electron microscope (EM) and showed potential as anti-HIV-1 agents in a viral infectivity assay against a wide range of laboratory-adapted as well as primary isolates in MT-2 cells and PBMC. In addition, the virions produced after the HIV-1 infected cells were treated with two of the most active compounds showed drastically reduced infectivity confirming the potential of these compounds as anti-HIV-1 agents. We have derived a comprehensive SAR from the antiviral data. The SAR analyses will be useful in further optimizing the leads to potential anti-HIV-1 agents. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21168336      PMCID: PMC3034313          DOI: 10.1016/j.bmc.2010.11.045

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  52 in total

Review 1.  Drug-like properties and the causes of poor solubility and poor permeability.

Authors:  C A Lipinski
Journal:  J Pharmacol Toxicol Methods       Date:  2000 Jul-Aug       Impact factor: 1.950

Review 2.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

3.  Image reconstructions of helical assemblies of the HIV-1 CA protein.

Authors:  S Li; C P Hill; W I Sundquist; J T Finch
Journal:  Nature       Date:  2000-09-21       Impact factor: 49.962

4.  Tripeptide interference with human immunodeficiency virus type 1 morphogenesis.

Authors:  Stefan Höglund; Jin Su; Sara Sandin Reneby; Akos Végvári; Stellan Hjertén; Ida-Maria Sintorn; Hillary Foster; Yi-Pyng Wu; Ingela Nyström; Anders Vahlne
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

5.  Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication.

Authors:  Brett M Forshey; Uta von Schwedler; Wesley I Sundquist; Christopher Aiken
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag.

Authors:  Jing Zhou; Chin Ho Chen; Christopher Aiken
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

7.  In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).

Authors:  Catherine S Adamson; Sherimay D Ablan; Ioana Boeras; Ritu Goila-Gaur; Ferri Soheilian; Kunio Nagashima; Feng Li; Karl Salzwedel; Michael Sakalian; Carl T Wild; Eric O Freed
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

8.  Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents.

Authors:  Young Ah Kim; Ashoke Sharon; Chung K Chu; Reem H Rais; Omar N Al Safarjalani; Fardos N M Naguib; Mahmoud H el Kouni
Journal:  Biochem Pharmacol       Date:  2007-01-21       Impact factor: 5.858

9.  1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors.

Authors:  Rabindranath Tripathy; Arup Ghose; Jasbir Singh; Edward R Bacon; Thelma S Angeles; Shi X Yang; Mark S Albom; Lisa D Aimone; Joseph L Herman; John P Mallamo
Journal:  Bioorg Med Chem Lett       Date:  2006-12-21       Impact factor: 2.823

10.  Mutation in the loop C-terminal to the cyclophilin A binding site of HIV-1 capsid protein disrupts proper virus assembly and infectivity.

Authors:  Samir Abdurahman; Stefan Höglund; Anders Höglund; Anders Vahlne
Journal:  Retrovirology       Date:  2007-03-19       Impact factor: 4.602

View more
  21 in total

1.  Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid.

Authors:  Sandhya Kortagere; Navid Madani; Marie K Mankowski; Arne Schön; Isaac Zentner; Gokul Swaminathan; Amy Princiotto; Kevin Anthony; Apara Oza; Luz-Jeannette Sierra; Shendra R Passic; Xiaozhao Wang; David M Jones; Eric Stavale; Fred C Krebs; Julio Martín-García; Ernesto Freire; Roger G Ptak; Joseph Sodroski; Simon Cocklin; Amos B Smith
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

Review 2.  Identification of HIV inhibitors guided by free energy perturbation calculations.

Authors:  Orlando Acevedo; Zandrea Ambrose; Patrick T Flaherty; Hadega Aamer; Prashi Jain; Somisetti V Sambasivarao
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  STRUCTURAL VIROLOGY. X-ray crystal structures of native HIV-1 capsid protein reveal conformational variability.

Authors:  Anna T Gres; Karen A Kirby; Vineet N KewalRamani; John J Tanner; Owen Pornillos; Stefan G Sarafianos
Journal:  Science       Date:  2015-06-04       Impact factor: 47.728

Review 4.  HIV type 1 Gag as a target for antiviral therapy.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-21       Impact factor: 2.205

Review 5.  New approaches for antiviral targeting of HIV assembly.

Authors:  Peter E Prevelige
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

6.  A HTRF based competitive binding assay for screening specific inhibitors of HIV-1 capsid assembly targeting the C-Terminal domain of capsid.

Authors:  Da-Wei Zhang; Rong-Hua Luo; Lei Xu; Liu-Meng Yang; Xiao-Shuang Xu; Gregory J Bedwell; Alan N Engelman; Yong-Tang Zheng; Shan Chang
Journal:  Antiviral Res       Date:  2019-06-27       Impact factor: 5.970

7.  In Silico Drug Discovery for Treatment of Virus Diseases.

Authors:  Shikha Joon; Rajeev K Singla; Bairong Shen
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

8.  Antiviral compounds modulate elasticity, strength and material fatigue of a virus capsid framework.

Authors:  Santos Domínguez-Zotes; Alejandro Valbuena; Mauricio G Mateu
Journal:  Biophys J       Date:  2022-02-11       Impact factor: 4.033

Review 9.  HIV-1 Capsid Inhibitors as Antiretroviral Agents.

Authors:  Suzie Thenin-Houssier; Susana T Valente
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

10.  Identification of a small molecule HIV-1 inhibitor that targets the capsid hexamer.

Authors:  Jimmy P Xu; Jeffrey D Branson; Rae Lawrence; Simon Cocklin
Journal:  Bioorg Med Chem Lett       Date:  2015-12-25       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.